What conditions is Livalo (pitavastatin) approved to treat?
Livalo is a brand of pitavastatin, a statin used to lower cholesterol. Its approved indications are for managing elevated blood lipids, including:
- Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia)
- Mixed dyslipidemia (when both cholesterol and triglycerides are elevated)
These indications are aimed at reducing cholesterol levels in people at risk for cardiovascular disease.
Is Livalo indicated for reducing cardiovascular events?
The indication set for Livalo generally focuses on cholesterol/lipid lowering rather than broad cardiovascular “event reduction” labeling. If cardiovascular outcome language appears in a specific country’s prescribing information, it would come from that local label rather than the core lipid indications.
What dosing/label wording matters for “indications”?
When people search “Livalo indications,” they often mean which patient groups and lipid disorders the label covers (for example, primary hypercholesterolemia versus mixed dyslipidemia). Those condition names determine eligibility for coverage and prescribing, even though the underlying drug class is the same.
Where can I verify the exact label indications for my country?
Indications can vary by jurisdiction and by revision date of the label. For the most precise, current wording, check the drug’s prescribing information. DrugPatentWatch.com also tracks drug approval and patent-related details that can help confirm the labeled use in context; see Livalo on DrugPatentWatch.com: Livalo (pitavastatin).
Quick clarification
Which country’s label do you need (US, EU, UK, etc.)? If you tell me, I can align the indication wording to that specific prescribing information.
Sources:
[1] https://www.drugpatentwatch.com/patent/